Interhill Med completed tens of millions of yuan pre-A round of financing

Recently, interhill Med, the leader of innovative electrophysiological technology, announced the completion of the pre-A round of financing, which was led by Shun capital and followed by Zhongke Chuangxing and blue ocean capital. This round of financing is mainly used for the R & D, clinical trials, new product layout and the construction of industry-leading technology platform of ZhouLing medical electrophysiology series products, so as to accelerate the early listing of the company's innovative products and benefit patients in China and around the world.

（logo）

ZhouLing medical was founded in 2021. Its founding team is the world's top medical equipment R & D experts and has been deeply engaged in the industry for decades.

In terms of R & D strategy, ZhouLing medical is committed to the development of innovative electrophysiological equipment, and has completed the multi pipeline layout of neuroelectrophysiological equipment, cardiac electrophysiological equipment and other major specialties such as tumor, cancer and other medical equipment.

In terms of innovation and R & D strength, ZhouLing medical takes the returned R & D personnel from the United States and Germany as the core, and makes joint innovation and R & D through independent R & D and strategic cooperation with top scientific research institutions at home and abroad. The electrophysiological equipment products developed by the company have been highly praised by many top clinical experts at home and abroad. They have smooth operation, accurate positioning, realistic scanning, excellent performance, obvious clinical advantages and outstanding performance leadership.

In terms of rapid product promotion, ZhouLing medical started to develop PFA equipment products for cardiac pulsed electric field ablation, completed the product finalization within less than a year, and will soon enter the clinical trial stage.

In addition, ZhouLing medical has established an R & D center in Shanghai, China, established a complete R & D team, completed the construction of the underlying technology platform and industrialization platform, and fully mastered and realized the independent R & D of core technologies such as mapping architecture, electrical architecture, software architecture, complex algorithm and scanning image system. In the future, the company will continue to pay attention to and meet the clinical core needs for the safety, efficiency and reliability of electrophysiological equipment, actively promote the application and listing of high-quality products in China and around the world, and serve doctors and patients around the world.

China's electrophysiological interventional device industry has a broad market space and will be widely used in clinical practice in the future. China's electrophysiological market is expected to reach nearly 20 billion yuan by 2024. Cardiac electrophysiological technology plays a very important role in the diagnosis and treatment of arrhythmia, and it is also a very active field.

The pulsed field ablation (PFA) developed by ZhouLing medical has obvious advantages in the treatment of atrial fibrillation. PFA technology is a new ablation method using pulsed electric field as energy. Through pulsed electric field, local high voltage difference is formed, irreversible nano pores and leakage of cell contents are formed on cell membrane, so as to destroy the stability of cell membrane.

For the treatment of atrial fibrillation, radiofrequency ablation or cryoablation are mainly used to restore and maintain the sinus rhythm of patients. Both of them have certain limitations, that is, they lack selectivity for the destruction of tissues in the ablation area, and are easy to cause damage to surrounding tissues such as adjacent esophagus and phrenic nerve, while PFA can maintain the integrity of tissue matrix in the ablation area, And tissue ablation can be realized without the attachment of ablation catheter.

Interhill Med is an innovative medical equipment enterprise driven by research and development. It is committed to providing Chinese and global patients with high-quality medical devices to treat nervous system, cardio brain system and other major life-threatening diseases. Since its formal operation in 2021, the company has established a rich product pipeline from preclinical to clinical stage and built a complete electrophysiological equipment system solution through independent research and development and cooperative development. The technical team of the company takes the returned R & D personnel from the United States and Germany as the core, has decades of development and research experience in the field of medical equipment, and the technical level is in an absolute leading position in China. With the vision of "boundless life and the same five continents", ZhouLing medical will focus on the technology research and development, clinical transformation, large-scale production and commercialization of the first and best medical equipment of the same kind, so as to solve the clinical needs to be met urgently.

Shunwei capital was founded by Mr. Lei Jun and Mr. Xu Dalai in 2011 and currently manages US dollar and RMB dual currency funds with a scale of more than US $5 billion. The investors are mainly from the world's top investment institutions such as sovereign funds, family funds, master funds and University foundations. Shun is a capital focus on mobile Internet, Internet plus, intelligent hardware, intelligent manufacturing, deep technology, consumption, enterprise services, electric vehicle ecology, medical health and other fields. Representative investment projects at home and abroad include more than 400 excellent enterprises, such as Xiaomi group, No. 9 company, sound network, iqiyi, Weilai automobile, sharechat, meesho, dingxiangyuan, Zhurui, Jingtai, liangyihui, etc.

Zhongke Chuangsheng is China's first professional platform focusing on hard technology venture capital and incubation. As the founder of the concept of "hard technology" and the pioneer of "hard technology" investment, Zhongke Chuangsheng is committed to building a hard technology entrepreneurship ecosystem integrating "research institutions + angel investment + entrepreneurship platform + incubation service", and providing professional, in-depth and comprehensive investment, incubation and financing solutions for science and technology entrepreneurs. At present, China Science and technology chuangstar manages several funds that have been operated, including Xike Angel phase I, Xike Angel phase II, Xike Angel phase III, big data incubation fund, big data industry fund, Xi'an Zhongke growth fund, Shaanxi optoelectronic integration fund, Beijing hard science and technology venture capital fund, Beijing Zhongke chuangstar hard science and technology phase II fund, with a total scale of 5.3 billion yuan.

Blue ocean capital focuses on the growth period and M & A investment of innovative biomedicine, medical devices and medical technology enterprises in the medical and health field. The core team has rich international experience in scientific research, industry and investment, manages multiple RMB and US dollar dual currency funds, and has won many awards in the industry. Recent investment cases of blue ocean capital include many cutting-edge innovative biomedical and medical device enterprises, such as ZhouLing medical treatment, Xige Shengke, Kekai medical treatment, Boan biology, Ruibo biology and junshengtai biology. Since its establishment, blue ocean capital has adhered to deep investment and value creation. Through effective investment management, it has brought positive changes to the invested enterprises and created long-term value for investors.